Metsera, Inc.’s (NASDAQ:MTSR) Quiet Period Will Expire Tomorrow

Metsera’s (NASDAQ:MTSR) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. During Metsera’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MTSR. Cantor Fitzgerald began coverage on Metsera in a research report on Tuesday, February 25th. They issued an “overweight” rating on the stock. Guggenheim initiated coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 price objective on the stock. Bank of America began coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price objective on the stock. Finally, Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company.

Metsera Trading Down 1.7 %

Shares of NASDAQ MTSR opened at $25.03 on Tuesday. Metsera has a fifty-two week low of $24.19 and a fifty-two week high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.